Baillie Gifford & Co. Purchases 62,503 Shares of Medpace Holdings, Inc. $MEDP

Baillie Gifford & Co. raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 12.0% during the third quarter, HoldingsChannel.com reports. The fund owned 584,796 shares of the company’s stock after buying an additional 62,503 shares during the quarter. Baillie Gifford & Co.’s holdings in Medpace were worth $300,679,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Wasatch Advisors LP lifted its stake in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the period. Mawer Investment Management Ltd. increased its holdings in Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after purchasing an additional 121,213 shares in the last quarter. AQR Capital Management LLC increased its holdings in Medpace by 15.1% in the second quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after purchasing an additional 81,637 shares in the last quarter. TD Asset Management Inc lifted its stake in Medpace by 15.6% in the second quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock valued at $143,636,000 after buying an additional 61,764 shares during the period. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of Medpace by 11.4% during the 2nd quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after buying an additional 45,435 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MEDP. BMO Capital Markets assumed coverage on shares of Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective for the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Robert W. Baird set a $613.00 price objective on shares of Medpace in a research report on Friday, October 24th. Truist Financial set a $555.00 target price on Medpace in a research report on Monday, October 27th. Finally, Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Medpace has an average rating of “Reduce” and a consensus target price of $491.27.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $588.05 on Friday. The company has a 50-day moving average price of $583.65 and a 200-day moving average price of $519.88. The stock has a market capitalization of $16.57 billion, a P/E ratio of 41.12, a P/E/G ratio of 2.04 and a beta of 1.43. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.01 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In related news, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the sale, the chief financial officer owned 6,000 shares in the company, valued at approximately $3,542,100. This represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the transaction, the chief executive officer owned 646,184 shares in the company, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 387,925 shares of company stock valued at $233,386,647 over the last ninety days. 20.30% of the stock is currently owned by insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.